PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo. 2022

Yonggang Sha, and Jian Wu, and Barry Paul, and Yue Zhao, and Parker Mathews, and Zhiguo Li, and John Norris, and Endi Wang, and Donald P McDonnell, and Yubin Kang
Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA.

Many patients with multiple myeloma (MM) have comorbidities and are treated with PPAR agonists. Immunomodulatory agents (IMiDs) are the cornerstones for MM therapy. Currently, little is known about how co-administration of PPAR agonists impacts lenalidomide treatment in patients with MM. Here, we determined the effects of PPAR agonists on anti-myeloma activities of lenalidomide in vitro and in a myeloma xenograft mouse model. Genetic overexpression and CRISPR/cas9 knockout experiments were performed to determine the role of CRBN in the PPAR-mediated pathway. A retrospective cohort study was performed to determine the correlation of PPAR expression with the outcomes of patients with MM. PPAR agonists down-regulated CRBN expression and reduced the anti-myeloma efficacy of lenalidomide in vitro and in vivo. Co-treatment with PPAR antagonists increased CRBN expression and improved sensitivity to lenalidomide. PPAR expression was higher in bone marrow cells of patients with newly diagnosed MM than in normal control bone marrow samples. High PPAR expression was correlated with poor clinical outcomes. Our study provides the first evidence that PPARs transcriptionally regulate CRBN and that drug-drug interactions between PPAR agonists and IMiDs may impact myeloma treatment outcomes.

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077269 Lenalidomide A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA. 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-,3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione,CC 5013,CC-5013,CC5013,IMiD3 Cpd,Revimid,Revlimid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D044767 Ubiquitin-Protein Ligases A diverse class of enzymes that interact with UBIQUITIN-CONJUGATING ENZYMES and ubiquitination-specific protein substrates. Each member of this enzyme group has its own distinct specificity for a substrate and ubiquitin-conjugating enzyme. Ubiquitin-protein ligases exist as both monomeric proteins multiprotein complexes. Ubiquitin-Protein Ligase,E3 Ligase,E3 Ubiquitin Ligase,Ubiquitin Ligase E3,Ubiquitin-Protein Ligase E3,Ligase E3, Ubiquitin,Ligase E3, Ubiquitin-Protein,Ligase, E3,Ligase, E3 Ubiquitin,Ligase, Ubiquitin-Protein,Ligases, Ubiquitin-Protein,Ubiquitin Ligase, E3,Ubiquitin Protein Ligase,Ubiquitin Protein Ligase E3,Ubiquitin Protein Ligases
D047492 Peroxisome Proliferator-Activated Receptors TRANSCRIPTION FACTORS that are activated by ligands and heterodimerize with RETINOID X RECEPTORS and bind to peroxisome proliferator response elements in the promoter regions of target genes. Peroxisome Proliferator-Activated Receptor,NUC1 PPAR,PPAR,PPAR, NUC1,Peroxisome Proliferator Activated Receptor,Peroxisome Proliferator Activated Receptors,Proliferator-Activated Receptor, Peroxisome,Proliferator-Activated Receptors, Peroxisome,Receptor, Peroxisome Proliferator-Activated,Receptors, Peroxisome Proliferator-Activated
D048868 Adaptor Proteins, Signal Transducing A broad category of carrier proteins that play a role in SIGNAL TRANSDUCTION. They generally contain several modular domains, each of which having its own binding activity, and act by forming complexes with other intracellular-signaling molecules. Signal-transducing adaptor proteins lack enzyme activity, however their activity can be modulated by other signal-transducing enzymes Signal Transducing Adaptor Proteins
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Yonggang Sha, and Jian Wu, and Barry Paul, and Yue Zhao, and Parker Mathews, and Zhiguo Li, and John Norris, and Endi Wang, and Donald P McDonnell, and Yubin Kang
January 2007, Bone,
Yonggang Sha, and Jian Wu, and Barry Paul, and Yue Zhao, and Parker Mathews, and Zhiguo Li, and John Norris, and Endi Wang, and Donald P McDonnell, and Yubin Kang
April 2014, British journal of cancer,
Yonggang Sha, and Jian Wu, and Barry Paul, and Yue Zhao, and Parker Mathews, and Zhiguo Li, and John Norris, and Endi Wang, and Donald P McDonnell, and Yubin Kang
April 2021, Cell biology and toxicology,
Yonggang Sha, and Jian Wu, and Barry Paul, and Yue Zhao, and Parker Mathews, and Zhiguo Li, and John Norris, and Endi Wang, and Donald P McDonnell, and Yubin Kang
November 1998, British journal of haematology,
Yonggang Sha, and Jian Wu, and Barry Paul, and Yue Zhao, and Parker Mathews, and Zhiguo Li, and John Norris, and Endi Wang, and Donald P McDonnell, and Yubin Kang
March 2019, Journal of hematology & oncology,
Yonggang Sha, and Jian Wu, and Barry Paul, and Yue Zhao, and Parker Mathews, and Zhiguo Li, and John Norris, and Endi Wang, and Donald P McDonnell, and Yubin Kang
February 2017, International journal of cancer,
Yonggang Sha, and Jian Wu, and Barry Paul, and Yue Zhao, and Parker Mathews, and Zhiguo Li, and John Norris, and Endi Wang, and Donald P McDonnell, and Yubin Kang
November 2021, Bioorganic chemistry,
Yonggang Sha, and Jian Wu, and Barry Paul, and Yue Zhao, and Parker Mathews, and Zhiguo Li, and John Norris, and Endi Wang, and Donald P McDonnell, and Yubin Kang
February 2013, Oncotarget,
Yonggang Sha, and Jian Wu, and Barry Paul, and Yue Zhao, and Parker Mathews, and Zhiguo Li, and John Norris, and Endi Wang, and Donald P McDonnell, and Yubin Kang
March 2005, Bioorganic & medicinal chemistry letters,
Yonggang Sha, and Jian Wu, and Barry Paul, and Yue Zhao, and Parker Mathews, and Zhiguo Li, and John Norris, and Endi Wang, and Donald P McDonnell, and Yubin Kang
September 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Copied contents to your clipboard!